Media Center

Events

2021
  • February - LSX World Congress
  • March - BIO-Europe Spring. Digital
2020
  • March - BIO-Europe Spring. Paris (France)
  • February - 15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug
  • January - J. P. Morgan (USA)
2019
  • November - BIO-Europe. Hamburg (Germany)
  • September - ESMO: European Society for Medical Oncology. Barcelona
  • June - BIO International. Philadelphia (USA)
  • June - ASCO Annual Meeting. Chicago (USA)
  • May - MIXiii-Biomed 2019. Tel Aviv (Israel)
  • January - Invest Securities BioMed Event
  • January - 2019 Cholangiocarcinoma Foundation Annual Conference. Salt Lake City (USA)
2018
  • October - Pau Muñoz will defend the Doctoral thesis: "Mechanism of action of the new antitumour drug ABTL0812: Role of pseudoquinase TRIB3, reticular stress and sphingolipids in death mediated by autophagy". UAB (Bellaterra, Barcelona)
  • October - Sachs Forum. Basel (Switzerland)
  • September - BioSpain. Sevilla (Spain)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • June - II Biennal Congress of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Rome (Italy)
  • May - Bio€quity Europe. Ghent (Belgum)
2017
  • November - BioEurope. Berlin (Germany)
  • October - CPhI Worldwide. Frankfurt (Germany)
  • September - ASEBIO Investors Day. Barcelona (Catalnoia)
  • September - Sachs Forum. Basel (Switzerland)
  • June - 2017 BIO International Convention. San Diego, CA (USA)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • March - BioEurope. Barcelona (Catalonia - Spain)
  • March - 10th Annual European Life Sciences CEO Forum & Exhibition. Zurich (Switzerland)
2016
  • October - BioEurope. Cologne (Germany)
  • October - CPhI. Barcelona (Catalonia, Spain)
  • June - BIO international convention. San Francisco, CA (USA)
  • September - BioSpain. Bilbao (Spain)
  • September - BioJapan (Japan)
2015
  • November - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA (USA)
  • September - ESMO: European Society for Medical Oncology. Vienna (Austria)
  • May - IATI Biomed. Tel Aviv (Israel)
  • May - Biotrinity. London (UK)
  • April - Anglonordic Life Science Conference. (Spain)
  • February - BIO CEO & Investor Conference. New York, NY (USA)
2013
  • April - BIO International Convention. Chicago, IL (USA)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)
  • March - Company presentation at 6th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
  • January - Company presentation at Biotech Showcase at JP Morgan Healthcare Conference. San Francisco, CA (USA)
2012
  • September - Poster session at the 8th International Translational Oncology Symposium. Barcelona
  • July - Poster session at the meeting of the European Association for Cancer Research (EACR). Barcelona (Catalonia, Spain)
  • June - Booth at BIO International Convention. Boston, MA (USA)
  • June - Company presentation at the International Cancer Cluster Showcase. Boston, MA (USA)
  • April - Poster session at the meeting of the American Association for Cancer Research (AACR). Chicago, IL (USA)
  • March - Company presentation at 5th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2011
  • November - Company presentation at NYC Landmark Venture Forum - Investing for Cures. New York, NY (USA)
  • November - Company presentation at Foro Neotec (CDTI). Logrono (Spain)
  • September - Company presentation at MassBio’s Global Gateway. Boston, MA (USA)
  • September - Company presentation at BioPharm America. Boston, MA (USA)
  • May - Company presentation at Oncology Forum Farmaindustria. Madrid (Spain)
  • June - BIO International Convention. Washington, DC (USA)
  • May - 7th International Translational Oncology Symposium. Barcelona (Catalonia, Spain)
  • April - BioTrinity. Newbury (United Kingdom)
  • January - Company presentation at 4th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2010
  • November - BioEurope. Munich (Germany)
  • November - Company presentation at European Venture Capital Contest Summit. Düsseldorf (Germany)
  • October - Company presentation at European Venture Capital Contest Semi-Final. Pamplona (Spain)
  • September - Company presentation at BioSpain. Pamplona (Spain)
  • August - Company presentation at European Venture Capital Contest Semi-Final. Aarhus (Denmark)
  • June - HiT Barcelona World Innovation Summit. Barcelona (Catalonia, Spain)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG